Serum levels of albumin-amyloid beta complexes are decreased in Alzheimer's disease

被引:41
作者
Yamamoto, Keiichi [1 ]
Shimada, Hiroyuki [1 ]
Koh, Hideo [2 ]
Ataka, Suzuka [1 ]
Miki, Takami [1 ]
机构
[1] Osaka City Univ, Grad Sch Med, Dept Geriatr Med & Neurol, Osaka 5458585, Japan
[2] Osaka City Univ, Grad Sch Med, Dept Hematol, Osaka 5458585, Japan
关键词
albumin; Alzheimer's disease; amyloid; biomarkers; serum; CSF BIOMARKERS; MOUSE MODEL; PLASMA; CLEARANCE; PROTEIN; BURDEN; BRAIN; IGG; CNS;
D O I
10.1111/ggi.12147
中图分类号
R592 [老年病学]; C [社会科学总论];
学科分类号
03 ; 0303 ; 100203 ;
摘要
AimDecreased amyloid (A) clearance from the brain to blood might play a key role in the development of Alzheimer's disease (AD). A is normally bound to and transported by albumin in blood, thus possibly maintaining constant concentration of free A in the blood. We therefore hypothesized that decreased blood levels of albumin-A complexes could be associated with decreased A removal from the brain to blood, resulting in A accumulation in the brain. MethodsWe carried out a cross-sectional investigation of the association between serum levels of albumin-A complexes (SLAAC) and AD prevalence in 89 patients who visited our outpatient clinic, and gave written informed consent between August 2008 and May 2012. ResultsWe confirmed 45 cases of AD. Low SLAAC was associated with an increased prevalence of AD (OR 0.27; 95% CI 0.14-0.51) in a univariable logistic model and multivariable logistic models. In addition, decreased SLAAC was associated with decreased levels of A42 in CSF (r=0.38, P=0.0221) and increased levels of p-tau in CSF (r=-0.43, P=0.0090), findings that have been shown to be associated with AD progression. ConclusionsThis novel method might be very useful for monitoring of the progression of AD. Geriatr Gerontol Int 2014; 14: 716-723.
引用
收藏
页码:716 / 723
页数:8
相关论文
共 31 条
[1]  
[Anonymous], 1995, JAMA, V274, P1627
[2]  
Becker RE, 2008, J ALZHEIMERS DIS, V15, P303
[3]   Amyloid beta-peptide is transported on lipoproteins and albumin in human plasma [J].
Biere, AL ;
Ostaszewski, B ;
Stimson, ER ;
Hyman, BT ;
Maggio, JE ;
Selkoe, DJ .
JOURNAL OF BIOLOGICAL CHEMISTRY, 1996, 271 (51) :32916-32922
[4]   Longitudinal stability of CSF biomarkers in Alzheimer's disease [J].
Blennow, Kaj ;
Zetterberg, Henrik ;
Minthon, Lennart ;
Lannfelt, Lars ;
Strid, Stig ;
Annas, Peter ;
Basun, Hans ;
Andreasen, Niels .
NEUROSCIENCE LETTERS, 2007, 419 (01) :18-22
[5]   AMYLOID-TARGETED THERAPEUTICS IN ALZHEIMER'S DISEASE: USE OF HUMAN ALBUMIN IN PLASMA EXCHANGE AS A NOVEL APPROACH FOR Aβ MOBILIZATION [J].
Boada, Merce ;
Ortiz, Pilar ;
Anaya, Fernando ;
Hernandez, Isabel ;
Munoz, Joan ;
Nunez, Laura ;
Olazaran, Javier ;
Roca, Isabel ;
Cuberas, Gemma ;
Tarraga, Lluis ;
Buendia, Mar ;
Pla, Ramon P. ;
Ferrer, Isidre ;
Paez, Antonio .
DRUG NEWS & PERSPECTIVES, 2009, 22 (06) :325-339
[6]   Frequency of stages of Alzheimer-related lesions in different age categories [J].
Braak, H ;
Braak, E .
NEUROBIOLOGY OF AGING, 1997, 18 (04) :351-357
[7]   Peripheral anti-Aβ antibody alters CNS and plasma Aβ clearance and decreases brain Aβ burden in a mouse model of Alzheimer's disease [J].
DeMattos, RB ;
Bales, KR ;
Cummins, DJ ;
Dodart, JC ;
Paul, SM ;
Holtzman, DM .
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA, 2001, 98 (15) :8850-8855
[8]   Brain to plasma amyloid-β efflux:: a measure of brain amyloid burden in a mouse model of Alzheimer's disease [J].
DeMattos, RB ;
Bales, KR ;
Cummins, DJ ;
Paul, SM ;
Holtzman, DM .
SCIENCE, 2002, 295 (5563) :2264-2267
[9]   AGE-RELATED CHANGE IN REDOX STATE OF HUMAN SERUM-ALBUMIN [J].
ERA, S ;
KUWATA, K ;
IMAI, H ;
NAKAMURA, K ;
HAYASHI, T ;
SOGAMI, M .
BIOCHIMICA ET BIOPHYSICA ACTA-PROTEIN STRUCTURE AND MOLECULAR ENZYMOLOGY, 1995, 1247 (01) :12-16
[10]   A RAPID FLAT GEL ISOELECTRIC-FOCUSING METHOD FOR THE DETERMINATION OF APOLIPOPROTEIN-E PHENOTYPES AND ITS APPLICATION [J].
ETO, M ;
WATANABE, K ;
ISHII, K .
CLINICA CHIMICA ACTA, 1985, 149 (01) :21-28